Menu
Recruiting NCT06728098

Safety and Tolerability Evaluation of Akkermansia Muciniphila

No phase Interventional Healthy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Probiotic, Maltodextrin.
Who it may be relevant to
Registry conditions: Healthy. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Indonesia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Safety and Tolerability Evaluation of Heat-Inactivated Akkermansia Muciniphila Akk11: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Overview

This is a randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Akkermansia muciniphila Akk11 in healthy adult.

Interventions

  • Dietary supplement Probiotic
    The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
  • Dietary supplement Maltodextrin
    The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).

Primary outcome measures

  • Changes in stool quality [Time frame: 30 days]

Eligibility criteria

Inclusion criteria

  • Male or Female subject age 18-60 years at screening.
  • Healthy subject according to investigator judgement based on screening data.
  • Subjects must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for the entire study.
  • Subjects who have not smoked in the past 1 month prior to screening.
  • Subjects with a healthy and balanced diet, including adequate fiber intake in their food consumption.
  • Subject or subject's legally acceptable representatives have the ability to comply with the trial protocol.
  • Signed informed consent from the subject or subject's legally acceptable representatives (must be obtained before any trial related activities).

Exclusion criteria

  • History of or presence of diabetes, immunodeficiency disorders, or chronic illness.
  • Regular use of medications known to affect the gastrointestinal system or alter gut microbiota composition, including but not limited to antibiotics, and immunosuppressants.
  • Have continuous, daily use of probiotics or probiotic containing products within 1 month prior to randomization.
  • Pregnant, planning a pregnancy or lactating female (urinary pregnancy test will be applied to female subjects at screening).
  • Change type of diet during study.
  • Any known allergy or intolerance to any of the ingredients in the formulation of the product under study.
  • History of drug, alcohol or other substance abuse, or other factors that limit their ability to cooperate during the study.
  • History of or presence of eating disorder.
  • Subject whose condition does not make them eligible to the study, according to the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Indonesia · 1 center
  • Fakultas Kedokteran Universitas Indonesia — Jakarta Pusat

Identifiers

NCT: NCT06728098 · WK2024017

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗